Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay

BACKGROUND: The 21-gene recurrence score (RS) (Oncotype DX(®); Genomic Health, Redwood City, CA) partitions hormone receptor positive, node negative breast cancers into three risk groups for recurrence. The Anne Arundel Medical Center (AAMC) model has previously been shown to accurately predict RS r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Gage, M M, Mylander, W C, Rosman, M, Fujii, T, Le Du, F, Raghavendra, A, Sinha, A K, Espinosa Fernandez, J R, James, A, Ueno, N T, Tafra, L, Jackson, R S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961181/
https://ncbi.nlm.nih.gov/pubmed/29788166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados